SCHEMBL266305

SCHEMBL266305

O=C(Nc1ccc(Br)cc1C(=O)N/N=C\c1ccc(Cl)c(C(F)(F)F)c1)c1ccc(C(S)c2ccncc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.42
RAB9A P51151 4/20 0.42
PKM P14618 2/20 0.42
POLB P06746 5/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 6/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
KMT2A Q03164 6/20 0.38
TDP1 Q9NUW8 4/20 0.38
CTDSP1 Q9GZU7 2/20 0.38
PLEC Q15149 1/20 0.38
PSMD14 O00487 1/20 0.38
THRB P10828 1/20 0.38
HPGD P15428 1/20 0.38
MEN1 O00255 4/20 0.37
KDM4E B2RXH2 1/20 0.37
MITF O75030 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267707 0.93 NPC1 (0.42) NPC1RAB9APKMPOLBLMNA
SCHEMBL267372 0.91 NPC1 (0.48) NPC1RAB9APKMPOLBLMNA
SCHEMBL267373 0.91 NPC1 (0.48) NPC1RAB9APKMPOLBLMNA
SCHEMBL273927 0.91 NPC1 (0.48) NPC1RAB9APKMPOLBLMNA
SCHEMBL269019 0.85 NPC1 (0.53) NPC1RAB9APKMPOLBLMNA
SCHEMBL266306 0.84 MAPT (0.42) NPC1RAB9APKMPOLBLMNA
SCHEMBL273401 0.84 MAPT (0.42) NPC1RAB9APKMPOLBLMNA
SCHEMBL266018 0.84 NPC1 (0.46) NPC1RAB9APKMPOLBLMNA
SCHEMBL267601 0.84 L3MBTL1 (0.53) NPC1RAB9APKMPOLBLMNA
SCHEMBL267209 0.83 KMT2A (0.50) NPC1RAB9APKMPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 NPC1 102/4885RAB9A 883/4885PKM 1697/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 NPC1 115/4885RAB9A 1362/4885PKM 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.